<DOC>
	<DOCNO>NCT01775761</DOCNO>
	<brief_summary>The purpose study investigate effect tafamidis interval electrocardiogram , specifically rate correct QT interval ( QTc ) healthy volunteer .</brief_summary>
	<brief_title>A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals , Specifically The Rate Corrected QT Interval ( QTc )</brief_title>
	<detailed_description />
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Healthy , nonsmoking , male and/or female subject nonchildbearing potential . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 . Total body weight &gt; 50 kg ( 110 lb ) . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease . An ALT AST measurement &gt; 2 time ULN . 12lead ECG demonstrate QTc &gt; 450 msec QRS interval &gt; 120 msec Screening . Subjects increase risk dose moxifloxacin , accord product label moxifloxacin . History risk factor QT prolongation torsades de pointes , congenital deafness family history sudden death .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Thorough QTc evaluation tafamidis compare effect moxifloxacin placebo healthy volunteer .</keyword>
</DOC>